FDA Commissioner Andrew von Eschenbach told a Senate Appropriations subcommittee that the agency believes batches of Baxter International's blood thinner heparin may have been contaminated "by virtue of economic fraud." After the hearing, however, von Eschenbach told reporters that the agency had no proof the contamination was committed on purpose.

Related Summaries